美国转移性癌症患者生命终末期的免疫治疗启动情况
该回顾性队列研究基于美国国家临床数据库,纳入242 371例转移性黑色素瘤、非小细胞肺癌或肾细胞癌患者,分析生命终末期(EOL)启动免疫治疗的特征与风险因素。结果显示EOL-I免疫治疗随时间增加,2019年超过1/14的免疫治疗在死亡前1个月内启动;转移器官≥3个者较仅淋巴结转移者死亡前1个月内启动免疫治疗的调整风险高3.8倍。
要点
- 2019年超过1/14的免疫治疗在死亡前1个月内启动。
- 转移器官≥3个者较仅淋巴结转移者死亡前1个月内启动免疫治疗的调整风险高3.8倍。
- 学术中心或高容量中心治疗者死亡前1个月内启动免疫治疗的 odds 分别降低31%和30%。
核心结论
- 生命终末期启动免疫治疗随时间增加。
- 转移负荷较高及在非学术或低容量机构治疗的患者接受EOL-I免疫治疗的 odds 更高。
- 追踪EOL-I免疫治疗可提供国家处方模式信息并预示晚期癌症临床策略变化。
研究设计与样本
- 回顾性队列研究,使用美国国家临床数据库,纳入转移性黑色素瘤、非小细胞肺癌或肾细胞癌患者,诊断时间在FDA批准相应免疫检查点抑制剂后至2019年12月。
- 共分析242 371例患者,包括20 415例IV期黑色素瘤、197 331例IV期NSCLC和24 625例IV期KCC。
- 平均随访13.7个月,数据分析时间为2022年12月至2023年5月。
主要发现
- 平均(SD)年龄67.9(11.4)岁,42.5%超过70岁,56.0%为男性,29.3%接受免疫治疗。
- 所有癌症类型中接受EOL-I免疫治疗的患者百分比随时间增加。
- 2019年超过1/14的免疫治疗在死亡前1个月内启动。
- 转移器官≥3个者较仅淋巴结转移者死亡前1个月内启动免疫治疗的调整风险高3.8倍(95% CI, 3.1-4.7; P < .001)。
- 学术中心较非学术中心治疗者死亡前1个月内启动免疫治疗的 odds 降低31%(OR, 0.69; 95% CI, 0.65-0.74; P < .001),高容量中心较极低容量中心降低30%(OR, 0.70; 95% CI, 0.65-0.76; P < .001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: While immunotherapy is being used in an expanding range of clinical scenarios, the incidence of immunotherapy initiation at the end of life (EOL) is unknown. OBJECTIVE: To describe patient characteristics, practice patterns, and risk factors concerning EOL-initiated (EOL-I) immunotherapy over time. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study using a US national clinical database of patients with metastatic melanoma, non-small cell lung cancer (NSCLC), or kidney cell carcinoma (KCC) diagnosed after US Food and Drug Administration approval of immune checkpoint inhibitors for the treatment of each disease through December 2019. Mean follow-up was 13.7 months. Data analysis was performed from December 2022 to May 2023. EXPOSURES: Age, sex, race and ethnicity, insurance, location, facility type, hospital volume, Charlson-Deyo Comorbidity Index, and location of metastases. MAIN OUTCOMES AND MEASURES: Main outcomes were EOL-I immunotherapy, defined as immunotherapy initiated within 1 month of death, and characteristics of the cohort receiving EOL-I immunotherapy and factors associated with its use. RESULTS: Overall, data for 242 371 patients were analyzed. The study included 20 415 patients with stage IV melanoma, 197 331 patients with stage IV NSCLC, and 24 625 patients with stage IV KCC. Mean (SD) age was 67.9 (11.4) years, 42.5% were older than 70 years, 56.0% were male, and 29.3% received immunotherapy. The percentage of patients who received EOL-I immunotherapy increased over time for all cancers. More than 1 in 14 immunotherapy treatments in 2019 were initiated within 1 month of death. Risk-adjusted patients with 3 or more organs involved in metastatic disease were 3.8-fold more likely (95% CI, 3.1-4.7; P < .001) to die within 1 month of immunotherapy initiation than those with lymph node involvement only. Treatment at an academic or high-volume center rather than a nonacademic or very low-volume center was associated with a 31% (odds ratio, 0.69; 95% CI, 0.65-0.74; P < .001) and 30% (odds ratio, 0.70; 95% CI, 0.65-0.76; P < .001) decrease in odds of death within a month of initiating immunotherapy, respectively. CONCLUSIONS AND RELEVANCE: Findings of this cohort study show that the initiation of immunotherapy at the EOL is increasing over time. Patients with higher metastatic burden and who were treated at nonacademic or low-volume facilities had higher odds of receiving EOL-I immunotherapy. Tracking EOL-I immunotherapy can offer insights into national prescribing patterns and serve as a harbinger for shifts in the clinical approach to patients with advanced cancer.
引用
- Kerekes DM, Frey AE, Prsic EH, et al. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. JAMA Oncol. 2024. PMID: 38175659. doi:10.1001/jamaoncol.2023.6025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。